Aspergillus osteomyelitis in a child who has p67-phox-deficient chronic granulomatous disease

Kurume Medical Journal

Volumn 46, Issue 1, 1999, Pages 87-90

  Tsumura, Naoki ^a   Akasu, Yuko ^a   Yamane, Hiromasa ^a   Ikezawa, Shigeru ^a   Hirata, Tomoshige ^a   Oda, Keiko ^a   Sakata, Yasutaka ^a   Shirahama, Masahiro ^a   Inoue, Akio ^a   Kato, Hirohisa ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Aspergillus osteomyelitis; Chronic granulomatous disease; Interferon gamma; Itraconazole; p67 phonx deficiency

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE; GAMMA INTERFERON;

ANTIBIOTIC THERAPY; ARTICLE; ASPERGILLUS FUMIGATUS; BONE RADIOGRAPHY; CASE REPORT; CHRONIC GRANULOMATOUS DISEASE; CLINICAL FEATURE; DEBRIDEMENT; DRUG EFFICACY; ENZYME DEFICIENCY; HUMAN; MALE; OSTEOMYELITIS; SCHOOL CHILD; TIBIA; TREATMENT OUTCOME;

EID: 0032982783     PISSN: 00235679     EISSN: None     Source Type: Journal    
DOI: 10.2739/kurumemedj.46.87     Document Type: Article

References (25)

1. Yamaguchi H, Uchida K, Kawasaki K, and Matsunaga T. In vitro activity of fluconazole, a novel bistriazole anti-fungal agent. Jpn J Antibiotics 1989; 42:1-16.
2. Smith RM, and Curnutte JT. Molecular basis of chronic granulomatous disease. Blood 1991; 77:673-686.
3. Abo A, Pick E, Hall A, Totty N, Teahan CG et al. Activation of the NADPH oxidase involves the small GTP-binding protein p21racl. Nature 1991; 353:668-670.
4. Sakiyama Y, Kuratsuji T, Nunoi H, Tatsuzawa O, Kobayashi Y et al. Effect of interferon-γ on chronic granulomatous disease: a joint study by 32 hospitals in Japan. J Jpn Pediatr Soc 1994; 98:1048-1056.
5. Weening RS, Adriaansz LH, Weemaes CMR, Lutter R, and Roos D. Clinical differences in chronic granulomatous disease in patients with cytochrome b-negative or cytochrome b-positive neutrophils. J Pediatr 1985; 107:102-104.
6. Tauber AI, Borregaard N, Simons E, and Wright J. Chronic granulomatous disease: A syndrome of phagocyte oxidase deficiencies. Medicine 1983; 62:286-309.
7. Weening RS, Kabel P, Pijman P, and Roos D. Continuous therapy with sulfamethoxazole-trimethoprim in patients with chronic granulomatous disease. J Pediatr 1983; 103:127-130.
8. Margolis DM, Melnick DA, Alling DW, and Gallin JI. Trimethoprim-sulfamethoxazole prophylaxis in the management of chronic granulomatous disease. J Infect Dis 1990; 162:723-726.
9. Mouy R, Fisher A, Vilmer E, Seger R, and Griscelli C. Incidence, severity, and prevention of infection in chronic granulomatous disease. J Pediatr 1989; 114:555-560.
10. Cohen MS, Isturiz RE, Malech HL, Root RK, Wilfert CM et al. Fungal infection in chronic granulomatous disease. The importance of the phagocyte in defense against fungi. Am J Med 1981; 71:59-66.
11. Denning DW, and Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2, 121 published cases. Rev Infect Dis 1990; 12:1147-1201.
12. Heinrich SD, Finney T, Craver R, Yin L, and Zembo MM. Aspergillus osteomyelitis in patients who have chronic granulomatous disease. J Bone Joint Surg 1991; 73:456-460.
13. Corrall CJ, Merz WG, Rekedal K, and Hughes WT. Aspergillus osteomyelitis in an immunocompetent adolescent: a case report and review of the literature. Pediatrics 1982; 70:445-461.
14. Sachs MK, Paluzzi RG, Moore JH Jr, Fraimow HS, and Ost D, Amphotericin-resistant aspergillus osteomyelitis controlled by itraconazole. Lancet 1990; 335:1475.
15. Neijens HJ, Frenkel J, Sabine MPF, Dzoljic-Danilovic G, Meradji M et al. Invasive aspergillus infection in chronic granulomatous disease: treatment with itraconazole. J Pediatr 1989; 115:1016-1019.
16. Mouy R, Veber F, Blanche S, Donadieu J, Brauner R et al. Long-term itraconazole prophylaxis against Aspergillus infections in thirty-two patients with chronic granulomatous disease. J Pediatr 1994; 125:998-1003.
17. Ezekowitz RAB, Dinauer MC, Jaffe HS, Orkin SH, and Newburger PE. Partial correction of the phagocyte defect in patients with X-linked chronic granulomatous disease by subcutaneous interferon gamma. N Engl J Med 1988; 319:146-151.
18. Bernhisel-Broadbent J, Camargo EE, Jaffe HS, and Lederman HM. Recombinant human interferon-γ as adjunct therapy for Aspergillus infection in a patient with chronic granulomatous disease. J Infect Dis 1990; 163:908-911.
19. Ohga S, Okamura J, Nakayama H, Nagatoshi Y, and Ueda K. Interferom-gamma therapy for infection control in chronic granulomatous disease. Acta Paediatr Jpn 1995; 37:315-320.
20. Weening RS, Leitz GJ, and Seger RA. Recombinant human interferon-gamma in patients with chronic granulomatous disease -European follow up study. Eur J Pediatr 1995; 154:295-298.
21. The International Chronic Granulomatous Disease Cooperative Study Group. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med 1991; 324:509-516.
22. Nathan CF, Murray HW, Wiebe ME, and Rubin BY. Identification of interferon-γ as lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med 1983; 158:670-689.
23. Thelen M, Wolf M, and Baggiolini M. Activation of monocytes by interferon-gamma no effect on the level or affinity of the nicotinamide dinucleotide-phosphate oxidase and on agonist-dependent superoxide formation. J Clin Invest 1988; 81:1889-1895.
24. Muhlebach TJ, Gabay J, Nathan CF, Erny C, Dopfer G et al. Treatment of patients with chronic granulomatous disease with recombinant human interferon gamma does not improve neutrophil oxidative metabolism, cytochrome b558 content or levels of four anti-microbial proteins. Clin Exp Immunol 1992; 88:203-206.
25. Ahlin A, Elinder G, and Palmblad J. Dose-dependent enhancements by interferon-gamma on functional responses of neutrophils from chronic granulomatous disease patients. Blood 1997; 89:3396-3401.